Surgery, Gastroenterology and Oncology
Vol. 23, No. 3, Jun 2018
Management of Hepatic Artery Thrombosis after Living Donor Liver Transplantation: Endovascular Thrombolytic Therapy or Surgical Intervention? Role of Hepatic Arterial Urokinase Infusion
Ashok Thorat, Long-Bin Jeng, Shih-Chao Hsu, Ping-Chun Li, Chun-Chieh Yeh, Te-Hung Chen, Horng-Ren Yang, Kin-Shing Poon
ORIGINAL PAPER, Jun 2018
Article DOI: 10.21614/sgo-23-3-159
The hepatic artery (HA) related complications after living donor liver transplantation (LDLT) remains an important cause of increased risk of post-transplant mortality. The timing of occurrence of hepatic artery thrombosis (HAT) after transplantation and the timely intervention are the determining factors in the survival of the recipients. Re-exploration and revision of the hepatic artery anastomosis or medical treatment with urokinase therapy are the lifesaving treatment options. We describe our successful outcome after arterial urokinase infusion as an initial therapy for the LDLT recipients with HAT.

Materials and Methods: From 10th September 2002 till 31st December 2017, a total of 908 LDLT surgeries were performed at China Medical University Hospital. A total of 12 patients that developed HAT in postoperative period were further studied. All the patients that were diagnosed to have HAT within 24 hours were re-explored whereas medical therapy with intraarterial urokinase infusion was the first treatment modality for the HAT developing after 24 hours of LDLT.

Results: 12 recipients (1.37%) developed HAT. Computed tomography (CT) angiography was done for all the recipients and arterial Urokinase infusion was given in 10 patients as the initial therapy whereas 2 patients were directly re-explored. All the urokinase treated patients had HAT 24 hours after LDLT. Five of the urokinase therapy patients developed complete re-canalization after urokinase therapy without any morbidity in post-transplant period.
After successful re-canalization, there was no evidence of arterial stenosis in subsequent follow up with satisfactory liver graft functions. Remaining five patients underwent re-exploration with revision of hepatic artery anastomosis (n=2) and re-transplantation (n=3).

Conclusions: Intra-arterial urokinase therapy is a feasible initial therapy in LDLT recipients with HAT with an acceptable HA recanalization rate that needs no further surgical intervention and can certainly be first choice of treatment in stable HAT patients. However, failure of re-canalization or deterioration of the patient's clinical condition warrants urgent surgical intervention.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 3353


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2024

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/